Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Lipfendra

Pharmaceutical Executive Daily: FDA Approves Lipfendra

Published 4 months ago
Description
In today's Pharmaceutical Executive Daily, FDA approves Merck's Lipfendra as the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly agrees to acquire AtaiBeckley for up to $3.8 billion, and a Pharmaceutical Executive podcast explores how better questions, not just more data, define strong biopharma leadership.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us